21.2.2024 08:03:23 CET | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

Thor Medical ASA will release its second half results on Wednesday 28 February
2024 at 07:00 am (CEST).

A presentation of the results followed by a Q&A session will be held on the same
day at 08:00 am at Carnegie's offices at Aker Brygge, Fjordalleen 16, and
through a live webcast. The presentation and the Q&A session can be followed
through a live webcast from our website www.thormedical.no -
https://www.thormedical.no or Thor Medical Webcast Q4 2023 (royalcast.com) -
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240228_3. 

DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

 * Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
   brede.ellingseter@thormedical.no 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visitwww.thormedical.no - https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/2924/4092/Download%20announcement
%20as%20PDF.pdf